BioSpace News Archive

Surmodics, Inc. today announced results for its fiscal 2021 fourth quarter ended September 30, 2021 and provided its financial outlook for its fiscal 2022.

Recursion Pharmaceuticals today reported business updates and financial results for its third quarter ending September 30, 2021.

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, announced that Ayala management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 5:00pm GMT.

Vaccitech plc, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, announced that Bill Enright, Chief Executive Officer, will be presenting at the Jefferies London Healthcare Conference.

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, announced third quarter 2021 financial results and a corporate update.

ChemoCentryx, Inc., announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences.

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced that the company has executed an exclusive license agreement with Leiden University Medical Centre (“LUMC”) for a first-in-class ex vivo lentiviral gene therapy for the treatment of RAG1 severe combined immunodeficiency (“RAG1-SCID”).

Hepion Pharmaceuticals, Inc. today announced that results from its Phase 2a ‘AMBITION’ NASH trial will be available as an e-poster at the Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases

Emalex Biosciences, Inc. (“Emalex”), today announced positive topline results from its Phase 2b clinical study (D1AMOND Study) evaluating the efficacy and safety of ecopipam (EBS-101), an investigational, first-in-class, dopamine-1 (D1) receptor antagonist, for the treatment of pediatric patients with Tourette Syndrome.

SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has received clearance to proceed with its Fibroblast Activation Protein Inhibitor (FAPI) clinical trial after completing a 30-day IND review with the FDA.